Revenio Group Oyj - Company Announcement

Revenio Group Corporation: FDA did not grant sales permit for Icare HOME in the US

Revenio Group Corporation, Stock Exchange Release, March 17, 2016 at
09:35

FDA DID NOT GRANT SALES PERMIT FOR ICARE HOME IN THE US

Icare Finland Oy, a subsidiary of Revenio Group, submitted in September a sales
permit application - for its Icare HOME tonometer for monitoring eye pressure at
home - to the United States Food and Drug Administration (FDA). The company has
now received information from the FDA that the sales permit was not granted in
the United States for Icare HOME.

Revenio will publish further inform about the impact of the negative decision as
soon as possible.

The Icare HOME tonometer has been granted a sales permit in all European
countries as well as Australia, Japan, South Korea, Brazil, Taiwan, Canada and
China.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims at developing
even more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating
margin for continuing operations standing at 28.4%. Revenio Group Corporation is
listed on Nasdaq Helsinki.

[HUG#1995453]